213.06MMarket Cap-13620P/E (TTM)
4.080High3.570Low1.01MVolume3.570Open3.550Pre Close3.95MTurnover3.08%Turnover RatioLossP/E (Static)53.94MShares13.70052wk High0.83P/B129.57MFloat Cap2.86052wk Low--Dividend TTM32.80MShs Float33.098Historical High--Div YieldTTM14.37%Amplitude2.250Historical Low3.912Avg Price1Lot Size
Fulcrum Therapeutics Stock Forum
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to ...
Fulcrum Therapeutics Enters Into a Collaboration and License Agreement With Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
No comment yet